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Objective: To estimate the prevalence of and risk factors for cardiovascular autonomic neurop-
athy (CAN) in adolescents and young adults with type 1 and type 2 diabetes enrolled in the
SEARCH for Diabetes in Youth Study.
Methods: The study included 1646 subjects with type 1 diabetes (age 18  4 years, diabetes
duration 8  2 years, HbA1c 9.1  1.9%, 76% non-Hispanic Whites) and 252 with type 2 dia-
betes (age 22  4 years, diabetes duration 8  2 years, HbA1c 9.2  3.0%, 45% non-Hispanic
Blacks). Cross-sectional and longitudinal risk factors were assessed at baseline and follow-up
visits. Area under the curve (AUC) was used to assess the longitudinal glycemic exposure and
cardiovascular risk factors. CAN was assessed by time and frequency domain indices of heart
rate variability (HRV). CAN was defined as the presence of ≥3 of 5 abnormal HRV indices.
Results: The prevalence of CAN was 12% in adolescents and young adults with type 1 diabetes
and 17% in those with type 2 diabetes. Poor long-term glycemic control (AUC HbA1c), high
blood pressure, and elevated triglyceride levels were correlates of CAN in subjects with type
1 diabetes. In those with type 2 diabetes, CAN was associated with elevated triglycerides and
increased urinary albumin excretion.
Conclusions: The prevalence of CAN in this multiethnic cohort of adolescents and young adults
with type 1 and type 2 diabetes are comparable to those reported in adults with diabetes. Sub-
optimal glycemic control and elevated triglycerides were the modifiable risk factors associated
with CAN.
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1 | INTRODUCTION
Cardiovascular autonomic neuropathy (CAN) is a serious complica-
tion of diabetes affecting the autonomic nerves innervating the
heart and blood vessels, with subsequent sympathovagal imbalance
and impact on heart rate regulation and cardiac performance.1–3
Although asymptomatic in earlier stages, CAN has been shown to
be an independent predictor of cardiovascular disease (CVD) mortal-
ity risk,4,5 silent myocardial ischemia6 and/or major CVD events,7
cardiac remodeling and left ventricular dysfunction,8 and progression
of diabetic nephropathy and chronic kidney disease.9,10 Yet, CAN is
one of the least recognized complications of diabetes, especially in
youth.
Reduction in the heart rate variability (HRV) parameters is the
earliest manifestations of CAN. Evaluation of HRV with time and fre-
quency domain indices are non-invasive methods to assess the pres-
ence and severity of CAN.2 Several small cross-sectional studies in
various pediatric populations, using diverse definitions, have reported
CAN prevalence estimates between 18% and 75%.11–15 In one of the
largest pediatric epidemiological studies assessing the burden of
diabetes-related complications in an Australian cohort of adolescents
with diabetes, Eppens et al found strikingly high prevalence of auto-
nomic neuropathy (using pupillometry) in adolescents with type 1 and
type 2 diabetes (61% and 57%, respectively).15
Apart from the SEARCH study, there have been no systematic
efforts to assess the burden of neuropathy, including CAN, in adoles-
cents and young adults with diabetes in the United States. We previously
reported that youth with type 1 diabetes have reduced HRV as com-
pared to age-matched healthy controls enrolled in the SEARCH CVD
study.16 Although, we have recently reported the age-adjusted preva-
lence of several diabetic complications (including CAN) in the SEARCH
participants as part of the SEARCH Cohort Study,17 the specific objective
of this study was to examine the prevalence of CAN more closely by age
group, diabetes duration, gender and race/ethnicity. Moreover, we were
specifically interested in examining the cross-sectional and longitudinal
risk factors (since diagnosis of diabetes to present) in adolescents and
young adults with type 1 and type 2 diabetes to better understand the
underlying risk factors and the pathological processes that drive CAN in
this young cohort.
The overall objectives of the current study were: (1) to estimate
the prevalence of CAN in a large, ethnically diverse cohort of adoles-
cents and young adults with type 1 and type 2 diabetes enrolled in
the SEARCH for Diabetes in Youth Study by age, gender, diabetes
duration and race/ethnicity; and (2) to identify the cross-sectional
and longitudinal risk factors for CAN.
2 | METHODS
2.1 | SEARCH for Diabetes in Youth Study
SEARCH for Diabetes in Youth Study is a prospective cohort study
following children and adolescents of diverse racial and ethnic back-
grounds diagnosed with diabetes at less than 20 years of age in the
United States.17 SEARCH participants are incident cases of diabetes
identified at 4 geographically defined populations in Ohio,
Washington, South Carolina, and Colorado, from health plan enrollees
in California, and from Indian Health Service beneficiaries from Amer-
ican Indian populations in Arizona and New Mexico.
2.2 | Study population
Adolescents and young adults with diabetes diagnosed at <20 years
of age were identified from a population-derived incident registry
network at 5 US sites by the SEARCH for Diabetes in Youth Registry
Study.17 Cases with newly diagnosed type 1 or type 2 diabetes in
2002-2006 or 2008, who completed a SEARCH baseline examination
(on average 9.3  6.4 months from diagnosis) and had at least
5 years of diabetes duration between 2011 and 2015, were recruited
into the SEARCH Cohort Study (2011-2015) (on average at 7.9  1.9
years from diagnosis) (Figure A1). Although the parent SEARCH
Cohort Study enrolled 2777 individuals, we excluded children
<10 years of age (n = 134) at the cohort visit, those with no diabetes
antibody measures for the etiological definition of diabetes (n = 440),
and those with incomplete neuropathy assessment (n = 305), which
reduced the analytic sample size to 1898 individuals (Figure A2).
Prior to protocol implementation, local institutional review board
approval was obtained for each center. Written informed consent
was obtained from participants 18 years and older, while assent with
parental written informed consent was obtained for participants
younger than 18 years.
2.3 | Baseline and cohort visits
The SEARCH baseline and cohort visits included a participant survey;
measurement of height, weight, waist circumference, blood pressure;
JAISWAL ET AL. 681
and blood and urine collection. Race and ethnicity were self-reported
and categorized as non-Hispanic White (NHW), non-Hispanic Black
(NHB), Hispanic, Asian or Pacific Islander, and Other. Current ciga-
rette smoking was defined as having smoked cigarettes on ≥1 of the
30 days preceding the visit. Individuals who had tried smoking or
smoked regularly (at least 1 cigarette every day for 30 days) but were
not current smokers were considered former smokers. Subjects who
had never smoked a whole cigarette were considered non-smokers.
Waist circumference was measured using the natural waist loca-
tion17 and divided by height in centimeters to calculate the waist-to-
height ratio (WHR). Body mass index (BMI) was defined as weight
(kg) divided by height2 (m). For participants <20 years of age, the
Centers for Disease Control and Prevention (CDC)-derived BMI z20
scores were used; for those ≥20 years the observed mean and SD
were used to standardize their BMI z20 values.
Resting systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured 3 times using an aneroid sphygmomanometer
while the participants were seated for at least 5 minutes, and the
average of the 3 measurements was taken.
A blood draw occurred after an 8-hour overnight fast, and medica-
tions, including short-acting insulin, were withheld the morning of the
visit. Blood samples were obtained under conditions of metabolic stabil-
ity, as defined by no episodes of diabetic ketoacidosis in the prior month.
Specimens were processed locally at the sites and shipped within
24 hours to the central laboratory (Northwest Lipid Metabolism and Dia-
betes Research Laboratories, University of Washington), where they
were analyzed for measurement of high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and
glycated hemoglobin (HbA1c) as previously described.17 Urinary albumin
and creatinine levels were assessed on a random spot urine sample to
evaluate renal function using the albumin-to-creatinine ratio (ACR). The
accuracy of HbA1c data was monitored by participation in the National
Glycohemoglobin Standardization Program, and the accuracy and con-
sistency of lipid data were monitored regularly by comparing results
obtained by enzymatic methods with those obtained by CDC reference
methods (CDC Reference Laboratory).18
In addition to a SEARCH baseline and a cohort visit, 57% of par-
ticipants (n = 1082) had one or more intermediate visits (at 1, 2, or
5 years after the baseline visit) at which the same cardio-metabolic
risk factors were measured, including HbA1c, lipids, waist circumfer-
ence, WHR, and BMI. The assay of biological samples has remained
consistent over time.
2.4 | Diabetes type
Diabetes type was defined using an etiological classification devel-
oped by SEARCH19 based on diabetes autoantibodies (glutamate
decarboxylase-2 [GAD-65], insulinoma-associated-2 antibodies [IA-
2A], and zinc-T8 autoantibody) and estimated insulin sensitivity score
(validated equation including waist circumference, HbA1c, and triglyc-
eride levels) at the baseline visit.19 Type 1 diabetes was defined as at
least 1 positive antibody, regardless of insulin sensitivity, or no posi-
tive antibodies and insulin sensitivity (score > 8.15). Type 2 diabetes
was defined as negative antibodies and insulin resistance
(score < 8.15).19
2.5 | Assessment of CAN
CAN was assessed by HRV testing using the SphygmoCor (AtCor,
Philadelphia, PA). SEARCH staff from each center was centrally
trained and certified to perform the HRV test. The HRV tests were
performed under standardized conditions that included overnight
fasting, avoidance of caffeine and tobacco products for 8 hours
before the test, and withholding prescriptions and over-the-counter
medicines (except for basal insulin) until testing was completed. Par-
ticipants underwent a 5-minute continuous electrocardiogram (ECG)
recording while supine after a 10-minute rest. All traces were
reviewed and analyzed to ensure that R-waves were adequately iden-
tified from artifacts and ectopic beats. The term “NN interval” is used
instead of RR interval of the ECG to emphasize that the processed
beats are normal sinus rhythm (ie, every QRS complex preceded a P-
wave). We analyzed the following time- and frequency-domain HRV
parameters from the SphgmoCor device: standard deviation of NN
interval (SDNN), root mean square difference of the successive NN
interval (RMSSD), high frequency (HF) power, low frequency
(LF) power, and LF:HF ratio. SDNN is a measure of overall HRV,
while the RMSSD and HF power represent the parasympathetic com-
ponent of the autonomic system and LF power the sympathetic com-
ponent. HRV test was considered abnormal if the values were below
the 5th percentile observed in 206 age- and sex-matched healthy
controls (age 10-28 years, 54% females) from the SEARCH CVD
study.16 CAN, as our primary outcome measure, was defined as the
presence of ≥3 abnormal HRV indices.
2.6 | Statistical analysis
2.6.1 | Cross-sectional data
Anthropometric, demographic, and metabolic data collected at the
cohort visit were used to compare the characteristics of adolescents
and young adults with and without CAN stratified by diabetes type.
Student’s t test and Wilcoxon 2-sample tests were used to com-
pare the distribution of normally and non-normally (triglycerides,
SDNN, RMSSD) distributed continuous variables, respectively, and
the χ2 test was used for categorical variables separately for type
1 and type 2 diabetes participants. Fisher’s exact test was used
whenever a cell count for a particular test was less than 5. The data
were presented as mean  SD for normally distributed variables and
as median (interquartile range, IQR) for non-normally distributed vari-
ables such as triglycerides and log transformation was done for
others such as ACR.
The prevalence of CAN was estimated overall and based on the
age at diagnosis (≥10 and <10 years) and duration of diabetes (5, 6-
10, and >10 years) separately for persons with type 1 or type
2 diabetes.
2.6.2 | Longitudinal data
In addition to the data collected at the baseline and cohort visit, the
area under the curve (AUC) was computed to summarize the longitu-
dinal trajectory of HbA1c and other continuous variables, such as
lipids, blood pressure, and BMI collected over time (at the baseline,
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1-, 2-, or 5-year follow-up and cohort visits), adjusting for the time
interval between the first and last measurement.
To assess the association of long-term glycemic control with
CAN, logistic regression models treating the presence of CAN as the
outcome were fitted separately for participants with type 1 and type
2 diabetes. These models were adjusted for potential confounders
(collected at current SEARCH cohort visit) such as age and sex
(Model 2), BMI (Model 3), blood pressure (Model 4), triglycerides
(Model 5), and ACR (Model 6). A fully adjusted model that included
all of these variables as covariates was also fitted (Model 7). Models
were stratified by diabetes type to limit confounding effects of age
and adiposity. Diagnostic tests were performed to ensure that model-
ing assumptions were satisfied. The data were analyzed using SAS
9.4 (SAS Institute, Cary, NC).
3 | RESULTS
Characteristics of adolescents and young adults with type
1 (n = 1646) and type 2 diabetes (n = 252) stratified by their CAN
status are shown in Table 1. The prevalence of CAN was 12% in ado-
lescents and young adults with type 1 diabetes, and 17% among
those with type 2 diabetes (Table 1). Subjects with type 1 diabetes
and CAN were older (mean age: 19  4 vs 18  4 years), more likely
to have developed diabetes at age 10 or older, and had a larger waist
circumference (81  12 vs 78  12 cm), higher blood pressure (SBP:
110  11 vs 106  11 and DBP 72  9 vs 69  9 mm Hg), poorer
glycemic control (HbA1c: 9.6  2.1% vs 9.1  1.8%), and elevated
levels of triglycerides (median [IQR] 82 [61 120] vs
74 [55 104] mg/dL) than those without CAN (all P < .05; Table 1).
Males with type 1 diabetes had a higher prevalence of CAN as com-
pared to females (15% vs 10%, P = .001). Subjects with type 2 diabe-
tes and CAN had higher DBP (80  12 vs 75  10 mm Hg) and
elevated triglyceride levels (median [IQR] 151 [102 254] vs
110 [78 183] mg/dL) and ACR (3.2  1.5 vs 2.7  1.7 mg/g) com-
pared to those without CAN (all P < .05; Table 1). Hispanic and NHW
subjects with type 2 diabetes had a higher prevalence of CAN (29%
and 27%, respectively) as compared to NHB (7%) and other minority
groups (12%) (P = .001).
The AUC for cardio-metabolic risk factors for CAN is depicted in
Table 2. Long-term poor glycemic control, summarized as AUC for
HbA1c, triglyceride levels (AUC triglycerides), and blood pressure
(AUC SBP and AUC DBP), were significantly higher among type 1 dia-
betes subjects with CAN as compared to those without CAN. Only
higher triglycerides over time were significantly associated with CAN
among subjects with type 2 diabetes (Table 2).
Table 3 summarizes the results from the multiple logistic regres-
sion analyses for the association between longitudinal glycemic con-
trol (AUC HbA1c as the independent variable) and CAN (dependent
variable) adjusted sequentially for covariates. Long-term poor glyce-
mic control (AUC HbA1c) was associated with CAN independent of
age, sex, blood pressure, BMI, triglyceride levels, and ACR in subjects
with type 1 diabetes, but not in those with type 2 diabetes (Table 3).
Since nearly 32% (n = 879) of the 2777 SEARCH participants
were excluded from the analysis dataset due to various reasons
(age < 10 years, missing etiological definition of diabetes type,
incomplete CAN assessment), we examined whether there were any
significant differences in the anthropometric, demographic, and meta-
bolic characteristics of the participants who were excluded vs
included in this dataset that could potentially affect the prevalence
estimates. Individuals excluded (n = 879) from the analysis were more
likely to have a longer duration of diabetes (9 vs 8 years, P < .001)
and were younger at the time of diabetes diagnosis (9 vs 11 years,
P < .001), as compared to those included in the analytic sample
(n = 1898) (Table A1).
4 | DISCUSSION
This study evaluating a large, multiethnic cohort of adolescents and
young adults in the United States found high prevalence of CAN in
subjects with type 1 and type 2 diabetes. Poor glycemic control and
higher triglyceride levels over time were consistently associated with
CAN. This is the first population-derived study in the United States
that carefully characterized differences in the cross-sectional and lon-
gitudinal risk factors for CAN in a large, racially/ethnically diverse
cohort of adolescents and young adults with type 1 and type
2 diabetes.
Placing our findings in perspective, in a meta-analysis including
3943 participants from 19 studies, the prevalence of subclinical CAN
defined by either cardiovascular reflex tests or baroreflex sensitivity
in young people (age < 24 years) with type 1 diabetes varied
between 16% and 75% depending on the outcomes reported.20 For
instance, in this meta-analysis pooled prevalence of CAN defined by
measures of HRV was 21%, and ranged from 4% to 11% if CAN was
defined by a single cardiovascular reflex test such as deep breathing
or Valsalva.20 In contrast, a relatively small study that assessed HRV
(LF and HF powers) and included only 20 pediatric patients with type
1 diabetes (mean diabetes duration: 7 years, mean HbA1c: 8.2%)
reported prevalence rates for CAN as high as 75%.11 The prevalence
estimates for CAN we found in the SEARCH cohort are lower com-
pared with those reported by Eppens et al in an Australian cohort
that included 1433 youth with type 1 and 68 type 2 diabetes who
found that 61% of youth with type 1 diabetes and 57% of those with
type 2 diabetes had evidence of autonomic neuropathy.15 However,
in that cohort autonomic neuropathy was defined as an abnormal
pupillometry test (assessed by measuring the pupil size before and
3 seconds after a light stimulus was delivered using an infrared pupill-
ometer).15 The difference in the method of assessment (pupillometry
vs HRV testing) likely explains the higher prevalence of autonomic
neuropathy in the Australian cohort, in spite of that cohort being
younger, with shorter diabetes duration and better glycemic control
compared with the SEARCH cohort.15 Although pupillometry was
considered in the past a simple non-invasive test to assess parasym-
pathetic autonomic function, it has not been widely used in the
research setting because of the lack of standardization in the tech-
niques employed, and the lack of validation studies. Thus, differences
in outcome definitions, type of autonomic dysfunction evaluated, and
the methods of assessments are the reasons accounting for the high
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variability in the prevalence reported in the few pediatric
populations.
Poor glycemic control, longer duration of diabetes, increasing age,
microalbuminuria, DBP, and dyslipidemia (lower HDL, increased
triglycerides) are some of the established risk factors for CAN in adults
with diabetes.1,21–25 This study found that poor glycemic control and
hypertriglyceridemia over time were the strongest risk factors associ-
ated with CAN in adolescents and young adults with type 1 diabetes.
TABLE 1 Clinical characteristics of adolescents and young adults with type 1 and type 2 diabetes stratified by cardiovascular autonomic
neuropathy status at the current SEARCH Cohort research visit (2011-2015)
Type 1 diabetes (n = 1646) Type 2 diabetes (n = 252)
Variable No CAN CAN P-value No CAN CAN P-value
N (%) 1443 (88%) 203 (12%) 209 (83%) 43 (17%)
Age (years) 18  4 19  4 <.0001 22  4 22  3 .99
Age at diagnosis (years) 10  4 11  3 <.0001 14.1  3 14  3 .82
Age at diagnosis ≥10 years 723 (84%) 137 (16%) <.0001 200 (83%) 40 (17%) .45
Age at diagnosis <10 years 720 (92%) 66 (8%) 9 (75%) 3 (25%)
Diabetes duration (years) 7.8  1.8 7.9  1.9 .44 7.9  1.9 7.8  2.0 .82
Diabetes duration (years)
5-10 1233 (88%) 167 (12%) .24 174 (82%) 38 (18%) .49
≥10 210 (85%) 36 (15%) 35 (87%) 5 (13%)
Sex
Female 746 (90%) 79 (10%) .001 141 (83%) 28 (17%) .77
Male 697 (85%) 124 (15%) 68 (82%) 15 (18%)
Race/ethnicity
Non-Hispanic White 1089 (87%) 158 (13%) .63 48 (73%) 18 (27%) .001
Asian/Pacific Islander 24 (92%) 2 (8%) 3 (100%) 0 (0%)
Non-Hispanic Black 143 (91%) 14 (9%) 105 (93%) 8 (7%)
Hispanic 175 (86%) 28 (14%) 37 (71%) 15 (29%)
Others 12 (87%) 1 (13%) 16 (88%) 2 (12%)
Smoking
Never 967 (89%) 122 (11%) .15 80 (84%) 15 (16%) .76
Former 259 (85%) 46 (15%) 61 (80%) 15 (20%)
Current 188 (86%) 30 (14%) 63 (84%) 12 (16%)
Oral diabetes medication
Yes 68 (87.2%) 10 (12.8%) .40 109 (82.6%) 23 (17.4%) .90
No 1372 (87.7%) 192 (12.3%) 99 (83.2%) 20 (16.8%)
Insulin dose 56.84  29.09 64.22  30.97 .0007 66.19  38.48 76.35  36.26 .20
Insulin dose, per kg 0.85  0.40 0.90  0.40 .06 0.73  0.39 0.86  0.36 .19
Waist circumference (cm) 78  12 81  12 .00011 104  19 111  20 .06
Waist-to-height ratio 0.5  0.1 0.5  0.1 .48 0.7  0.1 0.7  0.1 .33
BMI (kg/m2) 24  5 25  5 .12 35  9 37  9 .38
SBP (mm Hg) 106  11 110  11 <.0001 118  13 121  17 .36
DBP (mm Hg) 69  9 72  9 <.0001 75  10 80  12 .01
HbA1c (%) 9.1  1.8 9.6  2.1 .001 9.2  3 9.6  2.8 .42
HbA1c (mmol/mol) 75  7 80  8 .001 77  9 80  9 .42
HDL-C (mg/dL) 55  14 54  13 .15 42  12 39  10 .16
LDL-C (mg/dL) 96  28 99  32 .50 106  38 104  37 .88
Triglycerides (mg/dL) 74 (55 104) 82 (61 120) .005 110 (78 183) 151 (102 254) .002
CRP (mg/dL) 0.2  0.5 0.4  1.5 .74 0.6  0.8 0.7  0.7 .16
Log ACR (μg/mg) 2.0  0.93 2.1  0.95 .33 2.7  1.7 3.2  1.5 .014
Abbreviations: ACR, albumin:creatinine ratio; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; CRP, C-reactive protein; LDL-C, low-
density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP and DBP, systolic and diastolic blood pressure. All data are presented as
mean  SD or n (%) or median (IQR).
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There is ample biologic plausibility and evidence for the causal role of
hyperglycemia in the development and progression of chronic compli-
cations, including CAN.1,26–29 Hyperglycemia induces abnormal signal-
ing of the autonomic neurons via accumulation of advanced glycation
end products and microangiopathy, causing ischemic atrophy of auto-
nomic nerve fibers innervating cardiac and vascular tissues.30 In this
study, glucose control was quite poor in adolescents and young adults
with type 1 or type 2 diabetes, with a mean HbA1c of ~9%, far
exceeding the target HbA1c (<7.5%) recommended by the American
Diabetes Association.31 These data further confirm that there is an
urgent need for efforts focused at improving glycemic control among
adolescents and young adults with diabetes to mitigate the elevated
risk of the adverse outcomes associated with CAN and its downstream
consequences, including increased CVD risk.
Dyslipidemia has also been implicated in the pathogenesis of dia-
betic neuropathy in a non-glucocentric paradigm involving linked
metabolic and inflammatory insults that trigger
neurodegeneration.32–36 However, there is a close link between glu-
cose and lipid metabolism, as hypertriglyceridemia and reduced HDL
commonly occur in poorly controlled type 1 and type 2 diabetes.33
Hyperglycemia and dyslipidemia are also known as pro-inflammatory
triggers to the neurodegenerative processes.23 In a prior analysis of
youth participating in the SEARCH CVD study, we found an athero-
genic lipid profile in youth with type 1 diabetes and reduced HRV as
compared to age-matched healthy controls.16
The findings from this study have important clinical implications.
We observed that youth and young adults with type 1 and type 2 dia-
betes have evidence of CAN, as documented by changes in HRV at a
mean diabetes duration of 8 years. Emerging epidemiological evi-
dence also suggests that CAN is associated with increased arterial
stiffness in adolescents37 and adults38 with type 1 diabetes, and thus
could have an additive effect on the risk of future cardiovascular
events, which occur earlier and with poorer prognosis in individuals
with diabetes compared with the general population.4,39,40
Considering that SEARCH participants are a representative
cohort of US youth with diabetes and have suboptimal glycemic con-
trol (mean HbA1c well above the American Diabetes Association
recommended target of <7.5%),19 these data provide evidence that
screening for CAN, as is recommended for adults, may be beneficial
in adolescents and young adults,1 especially in those individuals who
have additional risk factors associated with CAN. Recent recommen-
dations from the American Heart Association call for a multifactorial
approach to mitigate the increased CVD risk in youth with diabetes.41
Thus, targeting poor glycemic control and dyslipidemia in adolescents
and young adults with diabetes as early as possible, which is also in
line with current standard of care in diabetes,31 could help mitigate
the increased CVD risk in this young population.28,36
The large sample size, multiethnic composition of the cohort, use
of a non-invasive, simple, validated instrument to assess CAN, and
evaluation of the longitudinal and cross-sectional risk factors are
TABLE 2 Cardio-metabolic risk factor burden over time by cardiovascular autonomic neuropathy status in adolescents and young adults with
type 1 and type 2 diabetes
Type 1 diabetes (n = 1646) Type 2 diabetes (n = 252)
Variable No CAN CAN P-value No CAN CAN P-value
AUC BMI z-score 20.6  0.9 20.6  0.9 .75 21.9  0.7 22  0.6 .50
AUC DBP 65.9  7.2 68  7.6 <.001 73.1  6.7 75.6  9.7 .18
AUC SBP 103.5  9 107.5  9 <.001 116.6  9.3 119.7  11.8 .22
AUC HbA1c 8.5  1.3 8.8  1.5 .005 8.4  2.4 8.6  2.3 .65
AUC LDL-C 93.5  22.3 95.1  24.2 .53 104.1  30.7 99.6  26.6 .54
AUC triglycerides 79.2  43.8 92  59.6 .001 149.6  121.7 225.3  221.8 .005
AUC HDL-C 56.1  11.8 54.7  10.6 .10 42.4  10.9 40.1  10.4 .13
Abbreviations: AUC, area under the curve derived from data collected at baseline, 1-, 2-, 5-year follow-up and the current cohort visits; BMI, body mass
index; CAN, cardiovascular autonomic neuropathy; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP and
DBP, systolic and diastolic blood pressure. All data are presented as mean  SD.
TABLE 3 Multivariable regression models for association between long-term glycemic control and cardiovascular autonomic neuropathy
collected at the current SEARCH Cohort Study (2011-2015)
Dependent variable: CAN
Type 1 diabetes Type 2 diabetes
Independent variable: AUC A1c adjusted for time between
measures OR (95% CI) P-value OR (95% CI) P-value
Model 1 = AUC A1c 1.28 (1.11; 1.48) .0006 1.07 (0.77; 1.48) .69
Model 2 = Model 1 + age, sex 1.3 (1.13; 1.5) .0002 1.07 (0.77; 1.49) .68
Model 3 = Model 1 + BMI 1.29 (1.11; 1.49) .0006 1.11 (0.79; 1.56) .54
Model 4 = Model 1 + SBP, DBP 1.26 (1.09; 1.47) .002 1 (0.71; 1.41) 1.00
Model 5 = Model 1 + Trig 1.22 (1.05; 1.43) .010 0.93 (0.65; 1.33) .69
Model 6 = Model 1 + ACR 1.26 (1.07; 1.47) .005 1.27 (0.86; 1.88) .22
Model 7 = Model 1 + age, sex, BMI, SBP, DBP, Trig, ACR 1.24 (1.04; 1.46) .01 1.08 (0.69; 1.7) .72
Abbreviations: ACR, albumin:creatinine ratio; AUC, area under the curve; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; CI, confi-
dence interval; OR, Odds ratio; SBP and DBP, systolic and diastolic blood pressure; Trig, triglycerides.
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among the strengths of our study. The limited power to examine the
association between long-term glycemic control and CAN among per-
sons with type 2 diabetes (despite similar levels of HbA1c to those
with type 1 diabetes) could be due to a comparatively small sample
size (although the association was in the same direction as that of the
type 1 diabetes group) is one of the limitations of our study. The lack
of longitudinal measures of CAN is also a limitation of our study,
although a subset of this cohort (2002-2012 incidence cases
≥10 years of age with least 5 years of duration of diabetes) will be
re-evaluated for CAN as part of the next phase of SEARCH (2016-
2020). Finally, although the SEARCH Cohort Study is drawn from
population-based registries of youth with diabetes, those excluded
from the analytic sample were more likely to be older at time of diag-
nosis and had a longer duration of diabetes. Each of these variables is
associated with increased prevalence of CAN and may influence our
estimates of CAN prevalence in youth and young adults with
diabetes.
Overall, the current data support the fact that good glycemic
control and better approaches to manage dyslipidemia are needed to
prevent the development and worsening of CAN in this young popu-
lation. Given the independent risk of CAN for cardiovascular events
and death, health care providers should motivate pediatric patients to
reach and maintain optimal glucose control and better management
of other risk factors including triglycerides to ameliorate the risk of
premature cardiovascular events.
ACKNOWLEDGEMENTS
The SEARCH for Diabetes in Youth Study is indebted to the many
youth and their families, and their health care providers, whose par-
ticipation made this study possible. Grant Support: SEARCH for Dia-
betes in Youth is funded by the Centers for Disease Control and
Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and
supported by the National Institute of Diabetes and Digestive and
Kidney Diseases. Site Contract Numbers: Kaiser Permanente South-
ern California (U48/CCU919219, U01 DP000246, and
U18DP002714), University of Colorado Denver (U48/CCU819241-3,
U01 DP000247, and U18DP000247-06A1), Children’s Hospital Med-
ical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and
1U18DP002709), University of North Carolina at Chapel Hill
(U48/CCU419249, U01 DP000254, and U18DP002708), University
of Washington School of Medicine (U58/CCU019235-4, U01
DP000244, and U18DP002710-01), Wake Forest University School
of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-
35171). The authors wish to acknowledge the involvement of the
South Carolina Clinical & Translational Research Institute at the Med-
ical University of South Carolina, NIH/National Center for Advancing
Translational Sciences (NCATS) grant number UL1 TR000062; the
Seattle Children’s Hospital and the University of Washington, NIH/N-
CATS grant number UL1 TR00423; the University of Colorado Pedi-
atric Clinical and Translational Research Center, NIH/NCATS grant
number UL1 TR000154; the Barbara Davis Center at the University
of Colorado at Denver (DERC NIH grant number P30 DK57516); the
University of Cincinnati, NIH/NCATS grant number UL1 TR000077;
and the Children with Medical Handicaps program managed by the
Ohio Department of Health. The findings and conclusions in this
report are those of the authors and do not necessarily represent the
official position of the Centers for Disease Control and Prevention
and the National Institute of Diabetes and Digestive and Kidney
Diseases.
Conflict of interest
All authors report no conflict of interest.
Author contributions
M.J., J.D., R.P.B., and D.D. designed the study and analysis plan. M.-
J. wrote the manuscript. J.D. performed the analysis and provided
critical input to the manuscript. R.P.B. reviewed data, provided input
in study design, and critically reviewed the manuscript for intellectual
content. E.M.U., D.D., R.A.B., D.J.P., G.I., C.P., L.M.D., A.D.L., S.M.,
B.L., and E.L.F. critically reviewed the manuscript and provided input.
J.D. is the guarantor of this work and, as such, had full access to all
the data in the study and takes responsibility for the integrity of the




1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a
position statement by the American Diabetes Association. Diabetes
Care. 2017;40(1):136-154.
2. Spallone V, Ziegler D, Freeman R, et al. Toronto consensus panel on
diabetic neuropathy. Cardiovascular autonomic neuropathy in diabe-
tes: clinical impact, assessment, diagnosis, and management. Diabetes
Metab Res Rev. 2011;27(7):639-653.
3. Pop-Busui R. What do we know and we do not know about cardio-
vascular autonomic neuropathy in diabetes. J Cardiovasc Transl Res.
2011;5(4):463-478.
4. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac auto-
nomic dysfunction on mortality risk in the action to control cardiovas-
cular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):
1578-1584.
5. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between
cardiovascular autonomic neuropathy and mortality in individuals with
diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895-1901.
6. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after
screening for asymptomatic coronary artery disease in patients with
type 2 diabetes: the DIAD study—a randomized controlled trial.
JAMA. 2009;301(15):1547-1555.
7. Pop-Busui R, Braffett BH, Zinman B, et al. Cardiovascular autonomic
neuropathy and cardiovascular outcomes in the diabetes control and
complications trial/epidemiology of diabetes interventions and com-
plications (DCCT/EDIC) study. Diabetes Care. 2017;40(1):94-100.
8. Pop-Busui R, Cleary PA, Braffett BH, et al. Association between car-
diovascular autonomic neuropathy and left ventricular dysfunction:
DCCT/EDIC study (diabetes control and complications trial/ epidemi-
ology of diabetes interventions and complications). J Am Coll Cardiol.
2013;61(4):447-454.
9. Orlov S, Cherney DZ, Pop-Busui R, et al. Cardiac autonomic neuropa-
thy and early progressive renal decline in patients with nonmacroal-
buminuric type 1 diabetes. Clin J Am Soc Nephrol. 2015;10(7):
1136-1144.
10. Wheelock KM, Jaiswal M, Martin CL, et al. Cardiovascular autonomic
neuropathy associates with nephropathy lesions in American Indians
with type 2 diabetes. J Diabetes Complications. 2016;30(5):873-879.
686 JAISWAL ET AL.
11. Boysen A, Lewin MAG, Hecker W, Leichter HE, Uhlemann F. Auto-
nomic function testing in children and adolescents with diabetes mel-
litus. Pediatr Diabetes. 2007;8:261-264.
12. Dalla Pozza R, Bechtold S, Bonfig W, et al. Impaired short-term blood
pressure regulation and autonomic dysbalance in children with type
1 diabetes mellitus. Diabetologia. 2007;50:2417-2423.
13. Mohsin F, Craig ME, Cusumano J, et al. Discordant trends in micro-
vascular complications in adolescents with type 1 diabetes from 1990
to 2002. Diabetes Care. 2005;28:1974-1980.
14. Riihimaa PH, Suominen K, Knip M, Tapanainen P, Tolonen U. Cardio-
vascular autonomic reactivity is decreased in adolescents with type
1 diabetes. Diabet Med. 2002;19:932-938.
15. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes
complications in adolescents with type 2 compared with type 1 diabe-
tes. Diabetes Care. 2006;29(6):1300-1306.
16. Jaiswal M, Urbina EM, Wadwa RP, et al. Reduced heart rate variabil-
ity among youth with type 1 diabetes: the SEARCH CVD study. Dia-
betes Care. 2013;36(1):157-162.
17. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type
1 diabetes vs type 2 diabetes diagnosed during childhood and adoles-
cence with complications during teenage years and young adulthood.
JAMA. 2017;317(8):825-835.
18. Myers GL, Kimberly MM, Waymack PW, Smith SJ, Cooper GR,
Sampson EJ. A reference method laboratory network for cholesterol:
a model for standardization and improvement of clinical laboratory
measurements. Clin Chem. 2000;46:1762-1772.
19. Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to char-
acterization of diabetes type: the SEARCH for diabetes in youth
study. Diabetes Care. 2011;34(7):1628-1633.
20. Tang M, Donaghue KC, Cho YH, Craig ME. Autonomic neuropathy in
young people with type 1 diabetes: a systematic review. Pediatr Dia-
betes. 2013;14:239-248.
21. Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior intensive
insulin therapy on cardiac autonomic nervous system function in type
1 diabetes mellitus: the diabetes control and complications trial/epi-
demiology of diabetes interventions and complications study
(DCCT/EDIC). Circulation. 2009;119:2886-2893.
22. Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is
associated with increased cardiovascular risk factors: the EURODIAB
IDDM Complications Study. Diabet Med. 2002;19:900-909.
23. Gottsäter A, Ahmed M, Fernlund P, Sundkvist G. Autonomic neuropa-
thy in type 2 diabetic patients is associated with hyperinsulinaemia
and hypertriglyceridaemia. Diabet Med. 1999;16:49-54.
24. Witte DR, Tesfaye S, Chaturvedi N, Eaton S, Kempler P, Fuller JH.
Risk factors for cardiac autonomic neuropathy in type 1 diabetes mel-
litus. Diabetologia. 2005;48:164-171.
25. Larsen JR, Sjøholm H, Berg TJ, et al. Eighteen years of fair glycemic
control preserves cardiac autonomic function in type 1 diabetes. Dia-
betes Care. 2004;27:963-966.
26. The Diabetes Control and Complications Trial Research Group. The
effect of intensive therapy of diabetes on the development and pro-
gression of long-term complications in insulin-dependent diabetes
mellitus. N Engl J Med. 1993;329:977-986.
27. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and
carotid intima-media thickness in type 1 diabetes mellitus. N Engl J
Med. 2003;348(23):2294-2303.
28. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
Multifactorial intervention and cardiovascular disease in patients with
type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
29. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic
neuropathy: lessons from recent large clinical trials. Curr Diab Rep.
2014;14(9):528.
30. Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and
diabetic cardiovascular disease. Cardiol Rev. 2012;20:177-183.
31. Standards of Medical Care in Diabetes—2016. Diabetes Care. 2016;
39(suppl 1):S86-S89.
32. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a
new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst.
2009;14:257-267.
33. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL.
Elevated triglycerides correlate with progression of diabetic neuropa-
thy. Diabetes. 2009;58(7):1634-1640.
34. Hur J, Sullivan KA, Pande M, et al. The identification of gene expres-
sion profiles associated with progression of human diabetic neuropa-
thy. Brain. 2011;134(11):3222-3235.
35. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the
common hypertriglyceridemia and low HDL cholesterol levels. Diabe-
tes. 1996;45(3):S27-S30.
36. Fried LF, Forrest KY, Ellis D, et al. Lipid modulation in
insulin-dependent mellitus: effect on microvascular outcomes. J Dia-
betes Complications. 2001;15(3):113-119.
37. Jaiswal M, Urbina EM, Wadwa RP, et al. Reduced heart rate variabil-
ity is associated with increased arterial stiffness in youth with type
1 diabetes: the SEARCH CVD Study. Diabetes Care. 2013;36(8):
2351-2358.
38. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA,
Orchard TJ. Cardiovascular autonomic neuropathy, HDL cholesterol,
and smoking correlate with arterial stiffness markers determined
18 years later in type 1 diabetes. Diabetes Care. 2010;33(3):652-657.
39. Liao D, Carnethon M, Evans G, Cascio W, Heiss G. Lower heart rate
variability is associated with the development of coronary heart dis-
ease in diabetics: the ARIC Study. Am J Epidemiol. 2000;151:S35.
40. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac
autonomic neuropathy in diabetic patients with or without silent
myocardial ischemia. Diabetes Care. 2001;24:339-343.
41. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease
risk factors in youth with diabetes mellitus: a scientific statement
from the American Heart Association. Circulation. 2014;130(17):
1532-1558.
How to cite this article: Jaiswal M, Divers J, Urbina EM,
et al. Cardiovascular autonomic neuropathy in adolescents
and young adults with type 1 and type 2 diabetes: The
SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabe-
tes. 2018;19:680–689. https://doi.org/10.1111/pedi.12633
JAISWAL ET AL. 687
APPENDIX
All registered cases of diabetes, 
current SEARCH sites (incident 
2002-2009)
N=11,139
Secondary DM cases 
N=327
Registered cases in incident years eligible for a 
baseline in-person visit (IPV) in SEARCH 1 
(2002-2005) and SEARCH 2 (2006, 2008) 
N=7,929 
Registered cases in incident 
years not eligible for a 
baseline IPV (2007, 2009) 
N=2,883
Participants with a 
baseline IPV 
N=4,095 
Participants with no 
baseline IPV  
N=3,834
Eligible for SEARCH 3 
Cohort visit         N=3,863
Not eligible for SEARCH 3 
Cohort visit           N=232
SEARCH 3 Cohort 
visit  N=2,777 
No SEARCH 3 Cohort visit
N=1,086
FIGURE A1 SEARCH 3 Consort diagram
TABLE A1 Characteristics of the participants excluded and included in the cardiovascular autonomic neuropathy analysis dataset at the current
SEARCH Cohort visit (2011-2015)
Variable Excluded (n = 879) Included (n = 1898) P-value
Age at cohort visit (years) 18  5 19  4 <.001
Age at diagnosis (years) 9  5 11  4 <.001
Sex (female, %) 53 52 .74
Diabetes duration (months) 104  24 95  23 <.001
Race/ethnicity .080
Non-Hispanic White (%) 63.8 69.3
Non-Hispanic Black (%) 18.7 14.1
Hispanic (%) 13.7 13.4
Asian/Pacific Islander (%) 1.9 1.5
Native Americans (%) 1.5 1.3
Other (%) 0.4 0.3
BMI z-score 0.8  1.2 0.7  1.1 .29
SBP (mm Hg) 102  14 102  13 .62
DBP (mm Hg) 64  11 64  10 .86
HbA1c (%) 9.2  2.1 9.2  2.1 .90
Triglycerides (mg/dL) 102  100 105  107 .43
LDL-C (mg/dL) 97  30 98  30 .49
HDL-C (mg/dL) 55  15 53  14 .06
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol, LDL-C, low-density lipoprotein cholesterol; SPB and DBP, systolic and
diastolic blood pressure. All data are presented as mean  SD or n (%).
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SEARCH 3 Cohort 
visit
N=2,777 
Youth < 10 years
N=134
SEARCH3 Cohort visit
Youth ≥ 10 years 
N=2,643




Youth ≥ 10 years






S  3 Cohort visit
Youth ≥ 10 years 
N=2,643
S  3 Cohort visit
Youth ≥ 10 years
with etiologic type  
N=2,251
FIGURE A2 Exclusion and inclusion
criteria
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